// App-Quantinova.ai

2617 : Phase 1 Study of ABT-348, A Dual Aurora/VEGF-Receptor Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies.

Researchers

Presenter

  • Raoul Tibes

Principal Investigators

  • Yi-Lin Chiu

  • Justin L. Ricker

  • H. Jean Khoury

  • Hao Xiong

  • Qin Qin

  • Peter Ansell

  • Daniel H. Albert

  • Chris Tse

  • Brian Oliver

  • Karim Sajwani

  • Mark D. McKee

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • Abbott

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Lymphocytic Leukemia

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

  • Hematological malignancies

  • Acute renal failure

  • Myelodysplastic Syndrome

  • Hypertension

  • Pancreatitis

  • Albuminuria

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • Platelet derived growth factor

  • Hepatocyte growth factor receptor

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Vidaza

  • Clofarabine

  • Adenosine

  • Adenosine Intravenous

  • L-Tyrosine

  • ilorasertib

  • Albert

  • oryzanol

  • Becaplermin

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • pharmacodynamics

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved